A new era for the systemic therapy of neuroendocrine tumors

Oncologist

Volumn 17, Issue 3, 2012, Pages 326-338

  Eads, Jennifer R ^a   Meropol, Neal J ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Carcinoid; Gastroenteropancreatic neuroendocrine tumor; Islet cell tumor; Neuroendocrine tumor; Pancreatic neuroendocrine tumor

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; CHLOROZOTOCIN; CISPLATIN; CIXUTUMUMAB; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GANITUMAB; IMATINIB; INTERFERON; IRINOTECAN; MOTESANIB; OCTREOTIDE; PASIREOTIDE; PAZOPANIB; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; UNINDEXED DRUG;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER STAGING; CANCER SURVIVAL; CARCINOID; CHEMOEMBOLIZATION; CLINICAL FEATURE; HUMAN; METASTASIS; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL NEOPLASMS; HORMONES; HUMANS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS;

EID: 84859393758     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0356     Document Type: Article

References (86)

1. Gaur P, Sceusi EL, Samuel S et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology 2011;141:1728-1737.
2. Niederle MB, Hackl M, Kaserer K et al. Gastroenteropancreatic neuroendocrine tumors: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010;17:909-918.
3. Yao JC, Hassan M, Phan A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26: 3063-3072.
4. Panzuto F, Boninsegna L, Fazio N et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 2011;29:2372-2377.
5. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
6. Fischer L, Kleeff J, Esposito I et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumors of the pancreas. Br J Surg 2008;95:627-635.
7. Tan EH, Tan CH. Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol 2011;2:28-43.
8. Pape UF, Jann H, Muller-Nordhorn J et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008;113:256-265.
9. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Neuroendocrine Tumors Version 1.2011, 2011. Available at http://www.nccn.org, accessed June 15, 2011.
10. Pinchot SN, Holen K, Sippel RS et al. Carcinoid tumors. The Oncologist 2008;13:1255-1269.
11. Edge SB, Byrd DR, Compton CC et al., eds. AJCC Cancer Staging Manual, Seventh edition. New York: Springer, 2009:1-646.
12. Kulke MH, Siu LL, Tepper JE et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011;29:934-943.
13. Oberg KE, Reubi JC, Kwekkeboom DJ et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010;139:742-753.
14. Reubi JC, Kvols LK, Waser B et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990;50:5969-5977.
15. Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-3410.
16. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513.
17. Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced lowto intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26:4311-4318.
18. Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76.
19. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
20. Duran I, Kortmansky J, Singh D et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148-1154.
21. Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010;37:594-618.
22. Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331:1199-1203.
23. Leotlela PD, Jauch A, Holtgreve-Graz H et al. Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 2003;10:437-450.
24. Gupta S, Yao JC, Ahrar K et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: The M.D. Anderson experience. Cancer J 2003;9:261-267.
25. Strosberg JR, Choi J, Cantor AB et al. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006;13:72-78.
26. Gupta S, Johnson MM, Murthy R et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005;104:1590-1602.
27. Akyildiz HY, Mitchell J, Milas M et al. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term followup. Surgery 2010;148:1288-1293.
28. Mazzaglia PJ, Berber E, Milas M et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007;142:10-19.
29. Kalinowski M, Dressler M, Konig A et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 2009;79:137-142.
30. Rhee TK, Lewandowski RJ, Liu DM et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008;247:1029-1035.
31. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973;79:108-118.
32. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;303:1189-1194.
33. Moertel CG, Lefkopoulo M, Lipsitz S et al. Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin the treatment of advanced isletcell carcinoma. N Engl J Med 1992;326:519-523.
34. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999;86:944-948.
35. McCollum AD, Kulke MH, Ryan DP et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004;27:485-488.
36. Kouvaraki MA, Ajani JA, Hoff P et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-4771.
37. Moertel CG, Kvols LK, O'Connell MJ et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232.
38. Turner NC, Strauss SJ, Sarker D et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010; 102:1106-1112.
39. Ramanathan RK, Cnaan A, Hahn RG et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma: Study of the Eastern Cooperative Oncology Group E-6282. Ann Oncol 2001;12:1139-1143.
40. Kulke MH, Stuart K, Enzinger PC et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-406.
41. Ekeblad S, Sundin A, Tiensuu Janson E et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-2991.
42. Kulke MH, Stuart K, Earle CC et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24(18S):4044.
43. Strosberg JR, Fine RL, Choi J et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-275.
44. Kulke MH, Hornick JL, Frauenhoffer C et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338-345.
45. Engstrom PF, Lavin PT, Moertel CG et al. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984;2:1255-1259.
46. Sun W, Lipsitz S, Catalano P et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005;23:4897-4904.
47. Bukowski RM, Tangen CM, Peterson RF et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 1994;73:1505-1508.
48. Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983;309:129-133.
49. Bajetta E, Zilembo N, Bartolomeo M et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferonalpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer 1993;72:3099-3105.
50. Saltz L, Kemeny N, Schwartz G et al. A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 1994;74:958-961.
51. Andreyev HJN, Scott-Mackie P, Cunningham D et al. Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 1995;13:1486-1492.
52. Frank M, Klose KJ, Wied M et al. Combination therapy with octreotide and alpha-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94: 1381-1387.
53. Arnold R, Rinke A, Klose KJ et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005;3:761-771.
54. Faiss S, Pape UF, Bohmig M et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21:2689-2696.
55. Kolby L, Persson G, Franzen S et al. Randomized clinical trial of the effect of interferon ÷ on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003;90:687-693.
56. Yao JC, Phan A, Hoff PM et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26:1316-1323.
57. Dahan L, Bonnetain F, Rougier P et al. Phase III trial of chemotherapy using 5-fluorouracil and streptozocin compared with interferon ÷ for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer 2009;16:1351-1361.
58. Guillemin R. Hypothalamic hormones a.k.a. hypothalamic releasing factors. J Endocrinol 2005; 184:11-28.
59. Rinke A, Muller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009;27:4656-4663.
60. Ch'ng JL, Anderson JV, Williams SJ et al. Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumors with long acting somatostatin analogue. Br Med J (Clin Res Ed) 1986;292:981-982.
61. Maton PN, O'Dorisio TM, Howe BA et al. Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N Engl J Med 1985;312:17-21.
62. Boden G, Ryan IG, Eisenschmid BL et al. Treatment of inoperable glucagonoma with the long acting somatostatin analog SMS 201-995. N Engl J Med 1986;314:1686-1689.
63. Kvols LK, Buck M, Moertel CG et al. Treatment of metastatic islet cell carcinoma with somatostatin analogue (SMS 201-995). Ann Intern Med 1987;107:162-168.
64. Kvols LK, Moertel CG, O'Connell MJ et al. Treatment of malignant carcinoid syndrome. Evaluation of a long acting somatostatin analogue. N Engl J Med 1986;315:663-666.
65. Levi S, Ellis M, Leung E et al. Long acting somatostatin in carcinoid syndrome [abstract]. Gut 1988;29:A714.
66. Saltz L, Trochanowski B, Buckley M et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993;72:244-248.
67. Kvols L, Wiedenmann B, Oberg K et al. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. J Clin Oncol 2006;24(18S):4082.
68. Frilling A, Weber F, Saner F et al. Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 2006; 140:968-977.
69. Waldherr C, Pless M, Maecke HR et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002;43:610-616.
70. Paganelli G, Bodei L, Handkiewicz Junak D et al. 90Y-DOTA-D-Phe1-Tyr3-octretide in therapy of neuroendocrine malignancies. Biopolymers 2002; 66:393-398.
71. Bodei L, Cremonesi M, Zoboli S et al. Receptor-mediated radionucide therapy with 90Y- DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003; 30:207-216.
72. 3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-422.
73. Kwekkeboom DJ, de Herder WW, Kam BL et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-2130.
74. De Jong M, Valkema R, Jamar R et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32:133-140.
75. Baum R, Wehrmann C, Zachert C et al. Longterm results of peptide receptor radionuclide therapy (PRRT): 5 year follow-up of 1,150 courses in 360 patients with progressive, somatostatin receptor positive neuroendocrine tumors in one clinical center. J Nucl Med 2007;48 (Suppl 2):37P.
76. Bushnell DL Jr., O'Dorisio TM, O'Dorisio MS et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010;28:1652-1659.
77. Claringbold PG, Brayshaw PA, Price RA et al. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011;38:302-311.
78. Kong G, Johnston V, Ramdave S et al. Highadministered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. Cancer Biother Radiopharm 2009;24:527-533.
79. Imhof A, Brunner P, Marincek N et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y- DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416-2423.
80. Bayer HealthCare Pharmaceuticals. Sorafenib prescribing information. 2011;1-20.
81. Hobday TJ, Rubin J, Holen K et al. MC044h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part 1, Vol 25, No 18S (June 20 Supplement); 2007:4504.
82. Yao JC, Zhang JX, Rashid A et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007;13:234-240.
83. Tolcher AW, Sarantopoulos J, Patnaik A et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-5807.
84. Anthony LB, Loehrer PJ, Leong S et al. Phase II study of cixutumumab (IMC-A12) plus depot octreotide for patients with metastatic carcinoid or islet cell carcinoma. J Clin Oncol 2010;28(15 suppl): TPS220.
85. Phan AT, Yao JC, Fogelman DR et al. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010;28(15 suppl):4001.
86. Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomized, placebo-controlled, phase 3 study. Lancet 2011;378:2005-2012.